Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

Expert Opinion on Investigational Drugs

Volumn 22, Issue 6, 2013, Pages 723-738

  Bose, Prithviraj ^a   Simmons, Gary L ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Alvocidib; Cyclin dependent kinase inhibitors; Dinaciclib; Flavopiridol; Mcl 1; PD0332991; Roscovitine; SCH727965; Seliciclib; Targeted therapies

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BRCA2 PROTEIN; CD135 ANTIGEN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; DINACICLIB; FLAVOPIRIDOL; GEMTUZUMAB OZOGAMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOXANTRONE; MYC PROTEIN; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PALBOCICLIB; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN MDM2; ROSCOVITINE; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; DIARRHEA; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DNA REPLICATION; DOWN REGULATION; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; FATIGUE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; MANTLE CELL LYMPHOMA; MITOSIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; PROLYMPHOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIDE EFFECT; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; HEMATOLOGIC NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS;

EID: 84878252263     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.789859     Document Type: Review

References (133)

1. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9(3):153-66
2. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24(11):1770-83
3. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 2001;7(8):2168-81
4. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005;23(36):9408-21
5. Wesierska-Gadek J, Maurer M, Zulehner N, Komina O. Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol 2011;226(2):341-9
6. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1(3):222-31
7. Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 2005;14(4):457-77
8. Hirose Y, Ohkuma Y. Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J Biochem 2007;141(5):601-8
9. Koumenis C, Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 1997;17(12):7306-16
10. Scrace SF, Kierstan P, Borgognoni J, et al. Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. Cell Cycle 2008;7(24):3898-907
11. Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999;96(8):4325-9
12. Yuan J, Yan R, Kramer A, et al. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004;23(34):5843-52
13. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3(3):233-45
14. Glaser SP, Lee EF, Trounson E, et al. Anti-apoptotic mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012;26(2):120-5
15. Michels J, O'Neill JW, Dallman CL, et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene 2004;23(28):4818-27
16. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002;99(6):1885-93
17. MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of mcl-1. Cancer Res 2005;65(12):5399-407
18. Raje N, Kumar S, Hideshima T, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of mcl-1 in multiple myeloma. Blood 2005;106(3):1042-7
19. Wuilleme-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005;19(7):1248-52
20. Chen R, Wierda WG, Chubb S, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009;113(19):4637-45
21. Chen S, Dai Y, Harada H, et al. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing bak activation and bax translocation. Cancer Res 2007;67(2):782-91
22. Nelson DM, Joseph B, Hillion J, et al. Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma 2011; 52(10):1999-2006
23. Kruse U, Pallasch CP, Bantscheff M, et al. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 2011;25(1):89-100
24. Dai Y, Hamm TE, Dent P, Grant S. Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107-and E2F-dependent S phase entry. Cell Cycle 2006;5(4):437-46
25. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3(11):1427-38
26. Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012;104(6):476-87
27. Cai D, Latham VM Jr, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006;66(18):9270-80
28. Pallis M, Burrows F, Whittall A, et al. Effectiveness of transcriptional CDK inhibitors in targeting non-proliferating CD34+CD38-AML cells. ASH Ann Meet Abstr 2011;118(21):3482
29. Johnson N, Shapiro GI. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 2010;14(11):1199-212
30. Maude SL, Enders GH. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Res 2005;65(3):780-6
31. Yu B, Dalton WB, Yang VW. CDK1 regulates mediator of DNA damage checkpoint 1 during mitotic DNA damage. Cancer Res 2012;72(21):5448-53
32. Esashi F, Christ N, Gannon J, et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 2005;434(7033):598-604
33. Santamaria D, Barriere C, Cerqueira A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007;448(7155):811-15
34. Ira G, Pellicioli A, Balijja A, et al. DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1. Nature 2004;431(7011):1011-17
35. Huertas P, Cortes-Ledesma F, Sartori AA, et al.K targets Sae2 to control DNA-end resection and homologous recombination. Nature 2008;455(7213):689-92
36. Jazayeri A, Falck J, Lukas C, et al. ATM-and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006;8(1):37-45
37. Deans AJ, Khanna KK, McNees CJ, et al. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res 2006; 66(16):8219-26
38. Zhu Y, Alvarez C, Doll R, et al. Intra-S-phase checkpoint activation by direct CDK2 inhibition. Mol Cell Biol 2004;24(14):6268-77
39. Zhu Y, Ishimi Y, Tanudji M, Lees E. Human CDK2 inhibition modifies the dynamics of chromatin-bound minichromosome maintenance complex and replication protein A. Cell Cycle 2005;4(9):1254-63
40. Wohlbold L, Merrick KA, De S, et al. Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbs1 as a Cdk2 substrate in human cells. PLoS Genet 2012;8(8):e1002935
41. Johnson N, Cai D, Kennedy RD, et al. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell 2009;35(3):327-39
42. Johnson N, Li YC, Walton ZE, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011;17(7):875-82
43. Radomska HS, Alberich-Jorda M, Will B, et al. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPalpha. J Clin Invest 2012;122(8):2955-66
44. Ney E, Lucas DM, Gupta SV, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood 2012;120(6):1262-73
45. Li L, Wang H, Kim J, et al. The cyclin-dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD. Cell Cycle 2009;8(11):1794
46. Parker BW, Kaur G, Nieves-Neira W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91(2):458-65
47. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2(10):RESEARCH0041
48. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276(34):31793-9
49. Decker RH, Dai Y, Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ 2001;8(7):715-24
50. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from cancer and leukemia group B study 19805. Clin Cancer Res 2005;11(11):4176-81
51. Dispenzieri A, Gertz MA, Lacy MQ, et al. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 2006;91(3):390-3
52. Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the national cancer institute of Canada clinical trials group. J Clin Oncol 2003;21(9):1740-5
53. Flinn IW, Byrd JC, Bartlett N, et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005;29(11):1253-7
54. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109(2):399-404
55. Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009;113(12):2637-45
56. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27(35):6012-18
57. Blum W, Phelps MA, Klisovic RB, et al. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 2010;95(7):1098-105
58. Jones JA, Kraut EH, Deam D, et al. Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia. Leuk Lymphoma 2012;53(3):490-1
59. Josefsberg Ben-Yehoshua L, Beider K, Shimoni A, et al. Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death. PLoS One 2012;7(4):e33856
60. Lacrima K, Rinaldi A, Vignati S, et al. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leuk Lymphoma 2007;48(1):158-67
61. Misra RN, Xiao HY, Kim KS, et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1, 1-dimethylethyl)-2- oxazolyl] methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004;47(7):1719-28
62. Chen R, Chubb S, Cheng T, et al. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res 2010;70(16):6587-97
63. Conroy A, Stockett DE, Walker D, et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009;64(4):723-32
64. Tong WG, Chen R, Plunkett W, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010;28(18):3015-22
65. Wu Y, Chen C, Sun X, et al. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor alpha and bcr-abl oncogene addiction in malignant hematologic cells. Clin Cancer Res 2012;18(7):1966-78
66. Walsby E, Lazenby M, Pepper C, Burnett AK. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia 2011;25(3):411-19
67. Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010;9(8):2344-53
68. Gorlick R, Kolb EA, Houghton PJ, et al. Initial testing (stage 1) of the cyclin-dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer 2012;59(7):1266-74
69. Johnson AJ, Yeh YY, Smith LL, et al. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 2012;26(12):2554-7
70. Sadowska M, Muvarak N, Lapidus RG, et al. Single agent activity of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in acute myeloid and lymphoid leukemia cells. ASH Ann Meet Abstr 2010;116(21):3981
71. Baiocchi RA, Flynn JM, Jones JA, et al. Early evidence of anti-lymphoma activity of the cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in heavily pre-treated low grade lymphoma and diffuse large cell lymphoma patients. ASH Ann Meet Abstr 2010;116(21):3966
72. Flynn JM, Jones JA, Andritsos L, et al. Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. ASCO Meet Abstr 2011;29(15-Suppl):6623
73. Gojo I, Walker A, Cooper M, et al. Phase II study of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in patients with advanced acute leukemias. ASH Ann Meet Abstr 2010;116(21):3287
74. Kumar SK, LaPlant BR, Chng WJ, et al. Phase 1/2 trial of a novel CDK inhibitor dinaciclib (SCH727965) in patients with relapsed multiple myeloma demonstrates encouraging single agent activity. ASH Ann Meet Abstr 2012;120(21):76
75. Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006;66(15):7661-7
76. Feng R, Huang X, Coulton L, et al. Targeting CDK4/CDK6 impairs osteoclast progenitor pool expansion and blocks osteolytic lesion development in multiple myeloma. ASH Ann Meet Abstr 2009;114(22):298
77. Marzec M, Kasprzycka M, Lai R, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006;108(5):1744-50
78. Wang L, Wang J, Blaser BW, et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007;110(6):2075-83
79. Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012;119(20):4597-607
80. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997;57(16):3375-80
81. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002;2(1):43-54
82. Karp JE, Ross DD, Yang W, et al. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin Cancer Res 2003;9(1):307-15
83. Karp JE, Passaniti A, Gojo I, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res 2005;11(23):8403-12
84. Karp JE, Blackford A, Smith BD, et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res 2010;34(7):877-82
85. Karp JE, Smith BD, Resar LS, et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 2011;117(12):3302-10
86. Karp JE, Garrett-Mayer EL, Estey EH, et al. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica 2012;97(11):1736-42
87. Zeidner JF, Gerber JM, Blackford A, et al. Randomized phase II trial of timed-sequential therapy (TST) with flavopiridol (alvocidib), ara-C and mitoxantrone (FLAM) versus "7+3" for adults ages 70 years and under with newly diagnosed acute myeloid leukemia (AML). ASH Ann Meet Abstr 2012;120(21):47
88. Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010;28(3):418-23
89. Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002;16(7):1331-43
90. Rosato RR, Almenara JA, Kolla SS, et al. Mechanism and functional role of XIAP and mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Mol Cancer Ther 2007;6(2):692-702
91. Gao N, Dai Y, Rahmani M, et al. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol 2004;66(4):956-63
92. Dasmahapatra G, Almenara JA, Grant S. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress bcl-2. Mol Pharmacol 2006;69(1):288-98
93. Rosato RR, Almenara JA, Cartee L, et al. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol Cancer Ther 2002;1(4):253-66
94. Rosato RR, Almenara JA, Yu C, Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004;65(3):571-81
95. Rosato RR, Almenara JA, Maggio SC, et al. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells. Mol Cancer Ther 2005;4(11):1772-85
96. Holkova B, Supko JG, Ames MM, et al. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res 2013;19(7):1-11
97. Cartee L, Wang Z, Decker RH, et al. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res 2001;61(6):2583-91
98. Cartee L, Smith R, Dai Y, et al. Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways. Mol Pharmacol 2002;61(6):1313-21
99. Cartee L, Maggio SC, Smith R, et al. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol. Mol Cancer Ther 2003;2(1):83-93
100. Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK-and NF-kappaB-dependent process. Oncogene 2003;22(46):7108-22
101. Dai Y, Rahmani M, Pei XY, et al. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and-independent mechanisms. Blood 2004;104(2):509-18
102. Holkova B, Perkins EB, Ramakrishnan V, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 2011;17(10):3388-97
103. Holkova B, Perkins EB, Bose P, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms-update of the "bolus" infusion schedule of alvocidib. ASH Ann Meet Abstr 2012;120(21):2959
104. Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 2002;8(9):2976-84
105. Bose P, Perkins EB, Honeycut C, et al. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with bcr-abl(+) hematological malignancies. Cancer Chemother Pharmacol 2012;
106. Chen S, Dai Y, Pei XY, et al. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res 2012;72(16):4225-37
107. Pei XY, Dai Y, Grant S. The small-molecule bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther 2004;3(12):1513-24
108. Rosato RR, Dai Y, Almenara JA, et al. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 2004;18(11):1780-8
109. Molinsky J, Klanova M, Koc M, et al. Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Leuk Lymphoma 2013;54(2):372-80
110. Yu C, Rahmani M, Dai Y, et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 2003;63(8):1822-33
111. Mohapatra S, Chu B, Zhao X, et al. Combined inhibition of CDK and PI3K/Akt pathways induces apoptosis of mantle cell lymphoma. ASH Ann Meet Abstr 2007;110(11):1384
112. Chiron D, Martin P, Liberto MD, et al. Induction of early G1-arrest by CDK4/CDK6 inhibition sensitizes mantle cell lymphoma cells to selective PI3K{delta} inhibition by GS-1101 through enhancing the magnitude and duration of p-AKT inhibition. ASH Ann Meet Abstr 2012;120(21):791
113. Blum KA, Wei L, Jones JA, et al. Activity of combined flavopiridol and lenalidomide in patients with cytogenetically high risk chronic lymphocytic leukemia (CLL): Updated results of a phase I trial. ASH Ann Meet Abstr 2011;118(21):3910
114. Huang X, Liberto MD, Jayabalan D, et al. Lenalidomide targets myeloma cells preferentially during prolonged early G1 arrest but not synchronization into S phase by selective and reversible inhibition of CDK4/CDK6 through loss of IRF-4. ASH Ann Meet Abstr 2010;116(21):449
115. Huang X, Di Liberto M, Jayabalan D, et al. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood 2012;120(5):1095-106
116. Menu E, Garcia J, Huang X, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res 2008;68(14):5519-23
117. Niesvizky R, Lentzsch S, Badros AZ, et al. A phase I study of PD 0332991: Complete CDK4/6 inhibition and tumor response in sequential combination with bortezomib and dexamethasone for relapsed and refractory multiple myeloma. ASH Ann Meet Abstr 2010;116(21):860
118. Niesvizky R, Costa LJ, Haideri NA, et al. Preliminary results of a phase 2 study of PD 0332991 in combination with bortezomib and dexamethasone in patients with relapsed and refractory multiple myeloma. ASH Ann Meet Abstr 2011;118(21):2940
119. Luke JJ, D'Adamo DR, Dickson MA, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res 2012;18(9):2638-47
120. Dai Y, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A. Cell Cycle 2002;1(2):143-52
121. Gao N, Kramer L, Rahmani M, et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5- methoxy-1, 3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of mcl-1 through a transcriptional mechanism. Mol Pharmacol 2006;70(2):645-55
122. Cirstea D, Hideshima T, Pozzi S, et al. RGB 286638, a novel multi-targeted small molecule inhibitor, induces multiple myeloma (MM) cell death through abrogation of CDK-dependent and-independent survival mechanisms. ASH Ann Meet Abstr 2008;112(11):2759
123. Zeng S, Li ZH, Chesi M, et al. Pre-clinical evaluation of a small molecule inhibitor of CDK1 as potential therapy for MYC expressing multiple myeloma tumors. ASH Ann Meet Abstr 2008;112(11):3667
124. Santo L, Vallet S, Hideshima T, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010;29(16):2325-36
125. Squires MS, Cooke L, Lock V, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther 2010;9(4):920-8
126. McMillin DW, Delmore J, Negri J, et al. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol 2011;152(4):420-32
127. Niepoth K, Gustavus D, Wenning D, et al. Anti-myeloma activity of LDC-000067, a novel selective inhibitor of cyclin-dependent kinase 9: A targeted approach. ASH Ann Meet Abstr 2011;118(21):5110
128. Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 2007;6(3):918-25
129. Manohar SM, Rathos MJ, Sonawane V, et al. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res 2011;35(6):821-30
130. Raje N, Hideshima T, Mukherjee S, et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009;23(5):961-70
131. Shirsath NP, Manohar SM, Joshi KS. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in both in vitro and in vivo mantle cell lymphoma cell lines. Mol Cancer 2012;11(1):77
132. Goh KC, Novotny-Diermayr V, Hart S, et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia 2012;26(2):236-43
133. Pallis M, Abdul-Aziz A, Burrows F, et al. The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells. Br J Haematol 2012;159(2):191-203